Investigating gene-diet interactions impacting the association between macronutrient intake and glycemic traits

Kenneth E. Westerman^{A1, 2, 3}, Maura E. Walker^{4, 5}, Sheila M. Gaynor⁶, Jennifer Wessel^{7, 8, 9}, Daniel DiCorpo¹⁰, Jiantao Ma¹¹, Alvaro Alonso¹², Stella Aslibekyan¹³, Abigail S. Baldridge¹⁴, Alain G. Bertoni¹⁵, Mary L. Biggs^{16, 17}, Jennifer A. Brody^{17, 18}, Yii-Der Ida Chen¹⁹, Joseé Dupuis¹⁰, Mark O. Goodarzi²⁰, Xiuqing Guo¹⁹, Natalie R. Hasbani²¹, Adam Heath²¹, Bertha Hidalgo²², Marguerite R. Irvin²³, W. Craig Johnson¹⁶, Rita R. Kalyani²⁴, Leslie Lange²⁵, Rozenn N. Lemaitre^{17, 26}, Ching-Ti Liu^{10, 27, 28, 29}, Simin Liu³⁰, Jee-Young Moon³¹, Rami Nassir³², James S. Pankow³³, Mary Pettinger³⁴, Laura Raffield³⁵, Laura J. Rasmussen-Torvik¹⁴, Elizabeth Selvin³⁶, Mackenzie K. Senn³⁷, Aladdin H. Shadyab³⁸, Albert V. Smith³⁹, Nicholas L. Smith^{40, 41, 42}, Lyn Steffen³³, Sameera Talegakwar⁴³, Kent D. Taylor¹⁹, Paul S. de Vries²¹, James G. Wilson⁴⁴, Alexis C. Wood³⁷, Lisa R. Yanek²⁴, Jie Yao¹⁹, Yinan Zheng¹⁴, Eric Boerwinkle^{21, 45}, Alanna C. Morrison²¹, Miriam Fornage²¹, Tracy P. Russell⁴⁶, Bruce M. Psaty^{17, 18, 40, 47}, Daniel Levy^{27, 48}, Nancy L. Head-Costa^{27, 49}, Vasan S. Ramachandran^{27, 28, 29}, Rasika A. Mathias²⁴, Donna K. Arnett⁵⁰, Robert Kaplan⁵¹, Kari E. North⁵², Adolfo Correa⁵³, April Carson⁵⁴, Jerome Rotter¹⁹, Stephen S. Rich⁵⁵, JoAnn E. Manson², Alexander P. Reiner⁴⁰, Charles Kooperberg³⁴, Jose C. Florez^{2, 3, 56, 57}, James B. Meigs^{2, 3, 58}, Jordi Merino^{2, 3, 59}, Deirdre K. Tobias^{60, 61}, Han Chen^{21, 62}, Alisa K. Manning^{A1, 2, 3}

^ = co-corresponding authors

AFFILIATIONS

- 1. Clinical and Translational Epidemiology Unit, Mongan Institute, Massachusetts General Hospital, Boston, MA.
- 2. Department of Medicine, Harvard Medical School, Boston, MA.
- 3. Programs in Metabolism and Medical and Population Genetics, Broad Institute of MIT and Harvard, Boston, MA.
- 4. Department of Medicine, Section of Preventative Medicine, Boston University School of Medicine, Boston, MA.
- 5. Department of Health Sciences, Sargent College of Health and Rehabilitation Sciences, Boston University, Boston, MA.
- 6. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.
- 7. Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indianapolis, IN.
- 8. Department of Medicine, Indiana University School of Medicine, Indianpolis, IN.
- 9. Department of Translation Research Center, Indiana University School of Medicine, Indianapolis, IN.
- 10. Department of Biostatistics, Boston University School of Public Health, Boston, MA.
- 11. Nutrition Epidemiology and Data Science, Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA
- 12. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
- 13. 23andme, Sunnyvale, CA.
- 14. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
- 15. Department of Epidemiology & Prevention, Wake Forest School of Medicine, Winston-Salem, NC.
- 16. Department of Biostatistics, University of Washington, Seattle, WA.
- 17. Cardiovascular Health Research Unit, University of Washington, Seattle, WA.

- 18. Department of Medicine, University of Washington, Seattle, WA.
- 19. The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA.
- 20. Department of Medicine, Division of Endocrinology Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA.
- 21. Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX.
- 22. Ryals School of Public Health, University of Alabama at Birmingham, Birmingham, AL.
- 23. Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL.
- 24. GeneSTAR Research Program, Johns Hopkins University School of Medicine, Baltimore, MD.
- 25. Department of Medicine, Anschutz Medical Campus, University of Colorado Denver, Aurora, CO.
- 26. Department of Internal Medicine, University of Washington, Seattle, WA.
- 27. National Heart Lung and Blood Institute and Boston University's Framingham Heart Study, Framingham, MA.
- 28. Evans Department of Medicine, Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, Boston, MA.
- 29. Evans Department of Medicine, Whitaker Cardiovascular Institute and Cardiology Section, Boston University School of Medicine, Boston, MA.
- 30. Center for Global Cardiometabolic Health (CGCH), Boston, MA.
- 31. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.
- 32. Department of Pathology, School of Medicine, Umm Al-Qura'a University, Mecca, Saudi Arabia.
- 33. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN.
- 34. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.
- 35. Department of Genetics, University of North Carolina, Chapel Hill, NC.
- 36. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
- 37. USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX.
- 38. Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA.
- 39. Department of Biostatistics, University of Michigan, Ann Arbor, MI.
- 40. Department of Epidemiology, University of Washington, Seattle, WA.
- 41. Kaiser Permanente Washington Health Research Institute, Seattle, WA.
- 42. Department of Veterans Affairs Office of Research and Development, Seattle Epidemiologic Research and Information Center, Seattle, WA.
- 43. Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia.
- 44. Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA.

- 45. Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX.
- 46. Department of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine, Burlington, VT.
- 47. Department of Health Systems and Population Health, University of Washington, Seattle, WA.
- 48. The Population Science Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, MD.
- 49. Department of Neurology, Boston University School of Medicine, Boston, MA.
- 50. College of Public Health, University of Kentucky, Lexington, KY.
- 51. Clinical Excellence Research Center, School of Medicine, Stanford University, Stanford, CA.
- 52. Department of Epidemiology, University of North Carolina, Chapel Hill, NC.
- 53. Department of Population Health Science, University of Mississippi Medical Center, Jackson, MS
- 54. Department of Medicine, University of Mississippi Medical Center, Jackson, MS.
- 55. Center for Public Health Genomics, Department of Public Health Sciences, University of Virginia, Charlottesville, VA.
- 56. Diabetes Unit, Massachusetts General Hospital, Boston, MA.
- 57. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
- 58. Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA.
- 59. Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
- 60. Department of Medicine, Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
- 61. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
- 62. Center for Precision Medicine, School of Public Health, The University of Texas Health Science Center, Houston, TX.

Conflicts of Interest

KEW has provided consulting services for FOXO BioScience. LMR is a consultant for the TOPMed Administrative Coordinating Center (through Westat).

Funding

KEW, HC, and AKM were supported by NIH R01 HL145025. LMR was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2TR002490 (LMR). VSR is supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine.

Corresponding Authors:

Kenneth E. Westerman kewesterman@mgh.harvard.edu

Alisa K. Manning akmanning@mgh.harvard.edu

1 **ABSTRACT**

2

3 Background: Heterogeneity in the long-term metabolic response to dietary macronutrient 4 composition can be partially explained by genetic factors. However, few studies have 5 demonstrated reproducible gene-diet interactions (GDIs), likely due in part to measurement error 6 in dietary intake estimation as well as insufficient capture of rare genetic variation. Discovery 7 analyses in ancestry-diverse cohorts that include rare genetic variants from whole-genome 8 sequencing (WGS) could help identify genetic variants modifying the effects of dietary 9 macronutrient composition on glycemic phenotypes.

10

11 **Objective:** We aimed to identify macronutrient GDIs across the genetic frequency spectrum 12 associated with continuous glycemic traits in genetically and culturally diverse cohorts.

13

14 Methods: We analyzed N=33,187 diabetes-free participants from 10 cohorts in the NHLBI

15 Trans-Omics for Precision Medicine (TOPMed) program with WGS, self-reported diet, and

16 glycemic traits (fasting glucose [FG], insulin [FI], and hemoglobin A1c [HbA1c]). We fit

17 multivariable-adjusted linear mixed models for the main effect of diet, modeled as an isocaloric

18 substitution of carbohydrate for fat, and for its interactions with genetic variants genome-wide.

19 Tests were performed for both common variants and gene-based rare variant sets in each cohort

- 20 followed by a combined cohort meta-analysis.
- 21

22 Results: In main effect models, participants consuming more calories from carbohydrate at the

23 expense of fat had modestly lower glycemic trait values (ß per 250 kcal substitution for FG: -24

0.030 mmol/L, *p*=2.7×10⁻⁶; lnFI: -0.008 log(pmol/L), *p*=0.17; HbA1c: -0.013 %, *p*=0.025). In 25 GDI analyses, a common African ancestry-enriched variant (rs79762542; 78 kb upstream of the

- *FRAS1* gene) reached study-wide significance ($p = 1.14 \times 10^{-8}$) indicating a higher HbA1c with 26
- 27 greater proportion of calories from carbohydrate vs. fat among minor allele carriers only. This
- 28 interaction was replicated in the UK Biobank cohort. Simulations revealed that there is (1) a

29 substantial impact of measurement error on statistical power for GDI discovery at these sample

30 sizes, especially for rare genetic variants, and (2) over 150,000 samples may be necessary to

- 31 identify similar macronutrient GDIs under realistic assumptions about effect size and measurement error.
- 32

33 34 **Conclusions:** Our analysis identified a potential genetic interaction modifying the dietary

35 macronutrient-HbA1c association while highlighting the importance of precise exposure

36 measurement and significantly increased sample size to identify additional similar effects.

- 37
- 38

39 **INTRODUCTION**

40

41 Diet is an established modifiable factor associated with risk of type 2 diabetes (T2D) and related

- 42 cardiometabolic diseases(1). However, evidence is mixed regarding the ideal dietary
- 43 macronutrient composition for risk reduction. Dietary interventions with differing proportions of
- 44 energy from carbohydrates versus fat have shown varied efficacy for T2D risk reduction and
- 45 substantial between-person heterogeneity in effects on cardiometabolic risk factors(2–4).
- 46 Further, acute glycemic responses to meals with specific macronutrient composition are
- 47 reproducible within individuals(5,6). Genetically different mouse strains have varying sensitivity
- 48 of glycemic biomarkers to a high-fat diet(7) and to human-relevant dietary patterns(8).
- 49 Retrospective analysis of human trials manipulating macronutrient intake have found genetic
- 50 modifiers of glycemic response(9). Taken together, such studies suggest that genetics could be a
- 51 key contributor to variability in the association between dietary macronutrient composition and glycemic health.
- 52
- 53

54 Gene-diet interaction (GDI) studies aim to identify genetic variants that modify the association

- 55 between dietary behaviors and health. Furthermore, GDI studies support differential associations
- 56 of dietary factors with glycemic traits according to genotypes, using both hypothesis-driven(10)
- 57 and hypothesis-free(11,12) strategies. However, in general, discovery and replication of gene-

58 diet interactions with T2D risk has been poor, possibly due to measurement error in assessing

- 59 habitual diet, low statistical power for interaction analysis, and biological and behavioral
- 60 heterogeneity across populations(13). Additionally, to date there has been little exploration of
- 61 GDIs involving rare genetic variants, which affect a smaller proportion of the population but
- 62 may have larger effect sizes(14).
- 63

64 Our primary aim was to discover novel putative genetic modifiers for the association between

- dietary macronutrient composition and glycemic traits. To this end, we performed a GDI analysis 65
- 66 using common and rare genetic variants in over 30,000 individuals with diverse ancestral
- 67 backgrounds from the NHLBI Trans-Omics for Precision Medicine (TOPMed) program. We
- focused on modeling a dietary carbohydrate-fat exchange, which can be reasonably assessed via 68
- 69 self-reported diet questionnaires and can be straightforwardly modified in the context of a
- 70 healthful diet. Furthermore, the use of whole-genome sequencing (WGS) permitted the analysis
- 71 of rare variants using set-based association tests. As a secondary aim, we sought to inform
- 72 subsequent GDI research by exploring the impact of dietary exposure measurement error on
- 73 statistical power in the context of realistic effect size estimates.

74 75 RESULTS

- 76
- 77 We analyzed data from 33,178 individuals without diabetes (based on FG, HbA1c, or medication
- 78 use) from 10 TOPMed program cohorts. Participants had diverse cohort-reported race/ethnicities
- 79 including: African American (N = 6,158), American Indian (N = 35), Asian (N = 124), white (N
- 80 = 19,721), and Hispanic/Latino (N = 7,114). Dietary carbohydrate and fat as a percentage of total
- 81 energy intake on average were 50.5% (standard deviation = 8.5%) and 32.2% (6.9%),
- 82 respectively, in the full pooled sample, estimated using validated food frequency questionnaires
- 83 (FFQ) or 24-hour dietary recalls (24HR). Cohort-specific carbohydrate intake estimates (as
- 84 percent of total energy [% kcal]), glycemic trait values (fasting glucose [FG], fasting insulin [FI;

- 85 or log-transformed, lnFI], and hemoglobin A1c [HbA1c]), and additional population
- 86 characteristics are presented in Supp. Table S1 and Supp. Fig. S1.
- 87

88 We first modeled the main association of macronutrient compositions with each of the glycemic

- 89 traits. By adjusting for total energy and energy from protein, resulting regression estimates for
- 90 carbohydrate represented a macronutrient exchange (increased 250kcals from carbohydrate
- 91 replacing an equivalent 250kcals from fat; see Methods). Meta-analysis of the individual cohorts
- 92 indicated that a higher proportion of kcal from carbohydrate at the expense of fat was associated
- 93 with lower FG (-0.030 mmol/L / 250kcals; $p = 2.2 \times 10^{-6}$), lnFI (-0.008 log(pmol/L) / 250kcals; p
- = 0.15), and HbA1c (-0.012 %HbA1c / 250kcals; p = 0.029). Forest plots of these results are shown in Supp. Fig. S2.
- 96

97 Common variant gene-diet interactions

98 99

100

101

102

103

104

105

106

107 108

109

We sought to identify macronutrient GDIs with the maximal sample available in TOPMed program cohorts in order to provide a baseline for discovery and evaluate our assumptions about expected effect sizes. Common variants (MAF > 1%) were analyzed in a primary, single-variant analysis of gene-carbohydrate interactions, with the same regression adjustments as above. This GDI analysis produces interaction estimates for the difference in the macronutrient-glycemic trait association per alternate allele at the variant of interest. After genome-wide, cohort-specific analysis and cross-cohort meta-analysis, one variant reached a study-wide significance threshold of 1.67×10^{-8} (5×10^{-8} / 3 glycemic traits). Two additional variants passed a standard genome-wide threshold of 5×10^{-8} (Table 1). We note that this threshold is liberal given the greater testing burden involved in the analysis of multiple ancestry groups(15). Of these three, none had evidence of a genetic main effect on the associated trait. Results are visualized in Supp. Fig. S3

- 110 for all variants and shown in Supp. Table S3 for variants with interaction $p < 10^{-5}$.
- 111

112 As the only variant reaching study-wide significance in the primary analysis, we looked deeper

113 into the biological function of rs79762542 and the functional form of its interaction. Variant

- 114 rs79762542 is observed on African-ancestry haplotypes and was discovered with respect to
- 115 HbA1c. The variant does not have known regulatory activity based on epigenomic assays in

116 RegulomeDB, but there is evidence for a role in regulating expression of the nearby gene

117 *FRAS1*, especially in thyroid, where this gene is most strongly expressed (GTEx project).

118 Colocalization analysis did not support a shared causal signal between our interaction results and

- 119 thyroid-specific eQTL signal (posterior probability of shared causal variant = 0.003%).
- 120

121 In genotype-stratified meta-analysis, HbA1c showed a modest negative association with

122 increasing carbohydrate relative to fat intake in major allele homozygotes (-0.033

123 %HbA1c/250kcals; p = 0.004) versus a positive association in minor allele carriers (0.10

124 %HbA1c/250kcals; p = 0.42) that may not have reached significance due to the much lower

sample size in this group (N = 1,055 across all studies). This genetic effect modification was

126 moderately consistent across the cohorts in which HbA1c levels were studied and the minor 127 allele of rs79762542 was observed (Fig. 1a,b; identical visualization in the African American

127 anele of 1879702342 was observed (Fig. 1a,b), identical visualization in the African American 128 reco/othnicity subset in Supp. Fig. S4a b). Figelly, with respect to the other glycomic traits in ou

128 race/ethnicity subset in Supp. Fig. S4a,b). Finally, with respect to the other glycemic traits in our

129 analysis, interaction effects were directionally consistent but did not reach nominal significance

130 (0.02 mmol/L/allele/250kcals; p = 0.07 for FG and 0.003 log(pmol/L)/allele/250kcals; p = 0.74

- 131 for $\ln FI$).
- 132

133 Lookups for the other two variants passing $p < 5 \times 10^{-8}$ revealed potential functional roles for

these variants. Variant rs1288694 (common in multiple ancestries) impacted FG in our analysis.

- 135 The variant is intronic to the *FOXP1* gene and may regulate splicing of the same gene (GTEx
- 136 project). FOXP1 has a demonstrated role in hepatic gluconeogenesis(16). Variant rs782681704 is
- 137 observed on African-ancestry haplotypes and was discovered with respect to FI in our analysis.
- 138 The variant is intronic to *BRCC3* and has likely regulatory activity (RegulomeDB score of 0.59)
- 139 but does not have clear evidence as an eQTL for *BRCC3*.
- 140
- 141 We explored these three prioritized single-variant loci through sensitivity analysis (Supp. Figs.
- 142 S5 [rs79762542] and S6 [all three variants]). Interaction effects were robust in population
- subsets: only males, only females, and individuals without obesity. Exclusion of individuals
- 144 either with or without prediabetes (beyond the predefined exclusion of individuals with diabetes)
- 145 partially attenuated the interaction signal; this might be expected due to the removal of a
- 146 substantial portion of the glycemic trait spectrum. Further, adjustment for either a diet quality
- score (AHEI-2010) or smoking status (along with their genotype interactions) did not
- 148 meaningfully impact estimates. Interaction estimates were also generally consistent in the
- 149 African American race/ethnicity subset, indicating that the interactions for African ancestry-
- 150 specific variants do not solely reflect population stratification.
- 151

152 Common variant replication

153


154 For the three prioritized single-variant loci, we tested for replication of these signals in the UK

155 Biobank (N=178,352 with 24-hour dietary assessment data(17) and glycemic biomarkers; see

- 156 Methods). Of these, 5,183 individuals were included in fasting glucose analyses (based on
- 157 fasting for at least eight hours prior to the associated blood draw). In the full, multi-ancestry
- 158 group (Supp. Table S5), we saw nominal replication of the interaction at rs79762542 with
- respect to both HbA1c (the discovery trait; p = 0.025) and fasting glucose (p = 0.013; Fig. 1c). Because most of the prioritized variants were specific to African-ancestry individuals, we
- 160 Because most of the prioritized variants were specific to African-ancestry individuals, we 161 conducted a similar replication in just this subgroup of the UK Biobank (Supp. Table S6). This

analysis supported the rs79762542 interaction influencing FG (p = 0.046).

163



164

Figure 1: Exploration of the rs79762542 interaction and replication. (a) Genotype-stratified dietary main effect estimates. (b) Stratified plots (one for each cohort with HbA1c available) display residualized HbA1c within strata defined by both genotype at rs79762542 (none vs. any minor alleles) and cohort-specific tertile of carbohydrate:fat ratio. (c) Similar stratified plots for the UKB replication cohort. For (b) and (c), the *y*-axis displays residuals after regressing the

170 relevant trait (HbA1c or FG) on the set of covariates used in the replication analysis.

171

172 **Rare variant interactions**

173

174 Rare variants (MAF < 1%) were analyzed in gene-centric, set-based tests, which help to 175 overcome power limitations for low-MAF variants by aggregating signal across multiple variants 176 annotated to the same gene. We used three variant aggregation strategies to define sets: selecting 177 missense variants, loss-of-function variants, or a broader coding + non-coding variant set 178 annotated to each gene (see Methods). No rare variant interaction signals showed genome-wide 179 significance (p < 0.05 / 28,111 total genes = 1.78×10^{-6} ; Supp. Table S4; Supp. Fig. S7).

180

181 Since the set of rare variants used does not overlap with those from the common-variant tests,

182 these gene-based tests can provide orthogonal evidence supporting common-variant signals

183 while further clarifying potential effector genes. Each of the three prioritized single-variant

184 findings were annotated to one or more genes based on proximity and/or expression-quantitative

185 trait locus (eQTL) data. None of these pairings showed supporting gene-based signal for the

186 corresponding glycemic trait, though the single study-wide significant variant (rs79762542,

187 discovered in relation to HbA1c) showed a nominal corresponding signal from the gene-based 188 test of *FRAS1* impacting FG (p = 0.028).

189

190 **Power calculations incorporating measurement error**

191

192 Given the modest discovery of GDIs despite the use of the maximal sample available within 193 TOPMed cohorts and substantial harmonization effort, we sought to better understand the 194 necessary power to detect expected GDI effects. Simulation-based power calculations for single-195 variant tests were conducted with added noise to account for the known random measurement 196 error in dietary data. Using literature-based anchors for expected effect sizes (Fig. 2a) and 197 assuming a conservative but realistic dietary measurement reliability of 0.5 (see Methods for 198 details), we established that a sample size of over 150,000 would be required to detect a GDI 199 effect of 0.025 % HbA1c / allele / s.d. carbohydrate at genome-wide significance for a variant 200 with MAF = 0.1 (Fig. 2b,c). As previously explored in the literature(18,19), power scaled 201 approximately linearly with exposure measurement fidelity. If we alternatively assume perfect 202 dietary exposure measurement, the associated sample size to detect the same effect was reduced 203 to about 80,000 indicating the importance of accounting for this measurement error. The 204 necessary sample size given realistic measurement reliabilities increased even further for lower-205 frequency variants (e.g., almost 1.2 million for MAF = 1%).

206

207 We extended this simulation-based power calculation approach to test multiple variants jointly,

208 mimicking the variant set-based test implemented for rare variants. Assuming similar

209 measurement fidelity and effect sizes as for single variants and fixing the sample size to match

210 the full sample used here (~35,000), an aggregate test of 20 rare variants with a causal fraction of


211 50% and MAF = 0.25% had negligible power (Fig. 2d). Power increased somewhat but remained

212 low when incorporating larger effect sizes (as are known to be present for rare variant main

effects on cardiometabolic traits)(20). For example, using an effect size of 0.1, approximately

equal to the largest genetic main effect on HbA1c reported by Wheeler and colleagues(21),

- 215 power increased to 0.16.
- 216



217

218 Figure 2: Power calculations for GEI incorporating exposure measurement error. For all plots 219 above, HbA1c is used as a basis for parameter choices. (a) Genetic and dietary effect sizes on 220 HbA1c for reference for potential interaction effects. (b) Simulation-based empirical power 221 estimates are shown as a function of the interaction effect (x-axis), minor allele frequency (MAF; panels left-to-right), and diet measurement reliability (colors). (c) Bar plots show the estimated 222 223 sample size needed to achieve 80% statistical power. Panels and colors are as in (b). (d) As in (a) 224 but modeling empirical power for simulated aggregate tests of 20 rare variants with a causal fraction of 0.1 or 0.5 (indicated in panel labels). Additional assumptions for these simulations 225 (full details in Methods): N = 35,000, phenotype mean of 5.5, phenotype standard deviation of 226 227 0.5, exposure mean of 0, exposure standard deviation of 1, genetic main effect of 0.01, and

228 environmental main effect of 0.2.

- 229
- 230
- 231

232 **DISCUSSION**

233

234 Our goal was to investigate genotype-related variability in the association of dietary

235 macronutrient composition with glycemic traits. Importantly, this was based on a regression

strategy modeling an isocaloric increase in dietary carbohydrate at the expense of fat(22). We

237 conducted our comprehensive analyses in cohorts with racial/ethnic diversity with data for both

common and rare variants from WGS. We examined multiple single variants with potential

239 modifying roles for the relationship of carbohydrate intake with glycemic traits, but did not find

substantial evidence from gene-based tests for a role of rare variants in modifying this diet-

241 glycemia relationship. Furthermore, our simulation-based power analysis highlighted the impact

of dietary measurement error on statistical power for the gene-diet interaction tests.

243

244 Dietary main effect models indicated that an increase in carbohydrate at the expense of dietary

fat was associated with lower fasting glucose and HbA1c. The impact of this macronutrient

exchange on glucose homeostasis and diabetes risk is complex and likely depends on the

247 respective macronutrient quality. Prior studies suggest null associations of total carbohydrate to

total fat exchange on diabetes risk(23,24). However, an exchange of animal-sourced fat for

249 carbohydrate or vegetable fat appears to have favorable associations with HbA1c(25,26).

250

251 Our primary genome-wide common variant interaction analysis yielded an interaction between a

252 250kcal carbohydrate-fat substitution and HbA1c with the African-ancestry rs79762542 variant,

253 which was validated in the UK Biobank. Genotype stratified analyses suggested that minor allele

carriers generally had a small negative association between carbohydrate and HbA1c (-0.033

255 %HbA1c/250kcals; p = 0.004) versus a larger but non-significant association in minor allele

carriers where the sample size was much lower (-0.10 %HbA1c/250kcals; p = 0.42). However, this precise pattern was not observed in all cohorts. These results warrant further exploration in

additional cohorts with African ancestry individuals and dietary intervention studies to examine

259 whether glycemic traits among minor allele carriers may benefit from higher fat and lower

260 carbohydrate diet composition. This primary discovery was made with HbA1c as an outcome,

but our results from set-based rare variant analysis and the UK Biobank replication suggest

similar patterns with respect to other traits such as FG. Beyond GDI discovery, the GWIS results

263 provided an opportunity to evaluate the effect size assumptions used in the power calculations.

For example, the rs79762542 interaction had an effect size of 0.048 %HbA1c/allele/250 kcal

265 carbohydrate, or 0.068 %HbA1c/allele/std. dev. carbohydrate. This effect size is somewhat larger

than, but of a similar magnitude to, the relevant anchor for the power analysis (the referenced

267 main effect association of carbohydrate with HbA1c(27)).

268

This analysis leveraged WGS data along with multi-variant set-based tests to better incorporate
 rare variants (minor allele frequency [MAF] < 0.01). While these variants don't contribute
 substantially to the overall population variance of glycemic or other traits, they tend to have

271 substantially to the overall population variance of glycenic or other traits, they tend to have 272 larger effect sizes and thus may be important for the specific individuals carrying them(14). For

example, phenylketonuria, a well-known inborn error of metabolism, acts through a rare-variant

GDI in which severe adverse effects of phenylalanine intake are seen only in individuals with a

275 particular genotype(28). In our study, despite helping to reinforce common variant signals, the

rare variant analysis did not contribute additional findings after aggregation at the gene level.

277 Substantially larger sample sizes will likely be necessary to uncover macronutrient GDIs

- involving rare variants.
- 279

280 We explored the statistical power for these interaction tests through simulations incorporating 281 random dietary measurement error using available simulation-based power calculation software 282 (ESPRESSO.GxE(29), for single variants) with additional extensions to allow for aggregate rare 283 variant tests. We estimated that substantially higher sample sizes (almost five times that used in 284 this study) are required for sufficient power to detect macronutrient-gene interactions at expected 285 effect sizes obtained from genetics and nutrition literature. This prompts two directions of further 286 inquiry. First, it suggests the importance of complementary approaches that assess where there is 287 any whole-genome contribution to the diet-glycemia association, at least in observational 288 datasets. These whole-genome analyses trade resolution for statistical power(30) and have a 289 precedent for GDIs in smaller study samples(31). Second, it reinforces the importance of 290 collecting dietary intake data in the growing group of large-scale biobanks and cohorts. 291 Improvements in study design, data collection methods, and analysis that can improve quality of 292 dietary assessments are also warranted. For example, conducting rigorous validation studies of 293 the data collection tools and approaches and ascertaining repeated dietary data can greatly 294 improve the precision of these measurements on a population level. Advancements in 295 objectively quantifying habitual diet from biospecimen samples are also underway and have

- 296 potential to improve discovery for genetic analyses.
- 297

An important strength of this study is the breadth of ethnic and cultural diversity of the sample

- (increasing the likelihood that findings are robust) and of genetic variation (with WGS dataenabling exploration of ancestry-specific genetic variation across the frequency spectrum). We
- 301 also conducted a systematic investigation into the available statistical power while incorporating
- 302 both realistic degrees of measurement error and evidence-based estimations of realistic effect
- 303 sizes for gene-macronutrient interactions. However, the diversity of the included study sample
- 304 also introduces heterogeneity that may be problematic. For example, the cohorts used different
- 305 dietary assessment tools to capture habitual intake, leading to differences in the degree and
- direction of random and systematic measurement error. This is compounded by general,
- 307 culturally-driven differences in food intake across race/ethnicity groups. Further heterogeneity
- arises from the time of data collection; the perceptions of carbohydrate intake have trended as
- 309 more and less healthful in recent decades, potential resulting in differential confounding between
- diet and other health-related behaviors depending on the time of data collection(32). Future work
- can step beyond broad macronutrient categories by harmonizing intakes of specific foods or
 dietary patterns and analyzing macronutrient subtypes (e.g., added sugar and specific fatty acids).
- 313 These approaches, combined with improved methods for detecting rare variant gene-
- 313 These approaches, combined with improved methods for detecting rate variant gene-314 environment interactions, will help utilize the increasing volume of WGS data to discover new
- environment interactions, will help utilize the increasing volume of WGS data to discover new
- 315 GDIs relevant for metabolic disease risk.
- 316

317 METHODS

318 Whole-genome sequencing

- 319 All genetic and phenotypic data used for this study were obtained from the NCBI Database of
- 320 Genotypes and Phenotypes (dbGaP) and the research was approved under the Mass General
- 321 Brigham IRB (protocol 2017P000531). WGS was conducted through the NHLBI TOPMed

- 322 program (Freeze 8 data release). Sequencing and alignment to the GRCh38 reference genome
- 323 was performed across six centers across the US: Broad Institute of MIT and Harvard, Northwest
- 324 Genomics Center, New York Genome Center, Illumina Genomic Services, PSOMAGEN
- 325 (formerly Macrogen), Baylor College of Medicine Human Genome Sequencing Center,
- 326 McDonnell Genome Institute (MGI) at Washington University. Data harmonization and joint
- 327 variant discovery and genotype calling were performed within the TOPMed Informatics
- 328 Research Center at the University of Michigan. Sequence quality control filters were as follows:
- estimated DNA sample contamination below 10% and at least 95% of the genome having
- 330 coverage of at least 10x. After genotyping, variants were further filtered for Mendelian
- inconsistency (based on a support vector machine classifier) and excess heterozygosity.
- Additional sample quality control was performed within the Data Coordinating Center at the University of Washington, including: matching sex as annotated and inferred from WGS,
- concordance of WGS genotypes with prior array-based "fingerprints", and agreement of inferred
- relatedness with expectations based on pedigrees. Additional details on the processing steps are
- 336 available at: https://www.nhlbiwgs.org/topmed-whole-genome-sequencing-methods-freeze-8.
- 337 Global measures of ancestry and relatedness were calculated on the entire TOPMed Freeze 8
- 338 sample by the TOPMed Data Coordinating Center. Genetic principal components reflecting
- ancestry were calculated using the PC-AiR method (allowing for related individuals)(33), and
- 340 kinship matrices were calculated using the PC-Relate method (accounting for principal
- 341 components)(34), both from the GENESIS R package. A sparse genetic relationship matrix
- 342 containing only relationships of degree four or closer was extracted for analysis. Samples were
- 343 grouped into race/ethnicity categories based on cohort-reported values.

344 Harmonization of glycemic traits

- 345 Phenotypes were harmonized across the 10 studies based on a protocol developed within the
- 346 TOPMed Diabetes Working Group. Glycemic traits, including fasting glucose (FG; mmol/L),
- fasting insulin (FI; pmol/L), and glycated hemoglobin (HbA1c; %), were collected where
- available. Fasting (for FG and FI) was defined as at least 8 hours without food or drink. FG
- measurements made in blood rather than plasma were adjusted by multiplying by a correction
- factor of 1.13. When multiple values were available for a given participant, blood draws were chosen to favor measurements made at study baselines and in order to maximize overlap with
- time points in which dietary data were collected. Participants were excluded if their glycemic
- 352 this points in which detaily data were concerted. Faitherparts were excluded if their grycenne 353 trait blood draw was more than one year before or after diet measurement or if they had diabetes
- (defined as any of: taking anti-diabetic medication, $FG \ge 7 \text{ mmol/L}$, or HbA1c $\ge 6.5\%$). Further
- 355 study-specific details are available in the Supplementary Methods. Phenotype data
- 356 harmonization and all other post-genome-wide analyses and visualizations were conducted using
- 357 R version 4.1.1(35). Unless otherwise noted, all analyses including harmonization were
- 358 performed on the NHLBI BioData Catalyst cloud computing platform(36).

359 Harmonization of dietary data

- 360 Estimates of dietary intake were derived from self-reported diet questionnaires, either food
- 361 frequency questionnaires (FFQ), diet history, or 24-hour recalls (24HR). Reported quantities of
- 362 food and beverage consumption were converted into daily nutrient intake estimates via standard
- 363 nutrient databases (see Supplementary Methods for study-specific details), with energy and
- 364 macronutrients (carbohydrate, protein and total fat) expressed in kilocalories/day (kcals/d).

365 Participants were excluded if responses were deemed implausible, based on having total caloric

intake <600 kcals/d or >4800 kcals/d. Nutrient intake values were analyzed in units of kcals/d

367 and winsorized at three standard deviations from the mean. Dietary fiber was represented in

368 grams/day (g/d) and alcohol intake was reported as number of drinks per day.

369 **Genome-wide gene-diet interaction scans**

370 For each cohort and glycemic trait, four genome-wide gene-diet interaction scans were

371 performed to identify diet-interacting loci: one for common variants, and three gene-based

372 aggregate tests for rare variants using different variant masks (described below). Mixed linear

373 models were used to allow for random effects of kinship capturing close family relationships

374 (degree four relatives or closer). The linear model setup was as follows:

$FG/lnFI/HbA1c \sim g + CHO + g * CHO + \gamma + covariates$

375 Where g is the genotype at the variant of interest, *CHO* is dietary carbohydrate intake (kcals/d),

and γ is a random effect governed by a sparse kinship matrix. General covariates included sex,

377 age, age², five genetic principal components to capture genetic ancestry, cohort-reported

378 race/ethnicity to capture potential confounding by ethnicity-related dietary behavior, and

additional study-specific covariates (Supp. Table S2). Dietary protein intake and total energy

(also expressed in kcals/d) were included as covariates to set up an isocaloric substitution model
 in which increases in CHO were implicitly exchanged for decreases in dietary fat. Dietary fiber

(g/d), alcohol intake (standard drinks/d), and body mass index (BMI; kg/m²) were included as

additional covariates to account for further lifestyle-related confounding. During null model

384 fitting, heterogeneous variances were allowed within each cohort-reported race/ethnicity group

385 (equivalent to including a random effect for this grouping variable).

386 Genome-wide interaction analysis was performed using the MAGEE package(37). Single-

variant analysis (*glmm.gei* function) was conducted for variants with MAF > 1%. METAL(38)

388 was used to perform fixed effects meta-analysis across cohorts. Specifically, the 2-degree of

389 freedom joint meta-analysis patch was used(39), with genetic main effect and interaction p-

390 values derived downstream based on the resulting effect and standard error estimates.

391 Gene-centric, set-based rare-variant analysis (MAGEE function) was conducted for variants with

392 MAF < 1%. Variant annotations derived from the WGSA v0.8 and WGSAParsr v6.3.8 were

393 retrieved from the NCBI dbGaP database. A genome-wide interaction meta-analysis was

394 conducted for each of three variant masks: loss of function variants

395 (VEP_ensembl_Consequence has terms *transcript_ablation*, *splice_acceptor_variant*,

396 *splice_donor_variant, stop_gained, frameshift_variant, stop_lost, start_lost* or

397 *transcript_amplification*), missense variants (VEP_ensembl_Consequence has the term

398 *missense_variant*), and a broad coding and noncoding filter (containing high-confidence loss-of-

399 function variants, missense variants, protein-altering variants, synonymous variants, variants

400 overlapping enhancers, and variants overlapping promoters). *MAGEE* calculates three interaction

401 p-values: an adjusted variance component-like test, a burden test (assuming a consistent direction

402 of effect for all variants), and a hybrid test (which combines the first two p-values using Fisher's

403 method). P-values from the hybrid test were used here to balance the increased power of the

- 404 burden test with the possibility that its assumption of homogeneous effect directions is violated.
- 405 Meta-analysis was then performed using a fixed-effects strategy.

406 Linear mixed models without genotype terms, meant to understand the marginal dietary effects 407 prior to considering genetic effects, were fit in R using analogous models to those with diet-

- 407 phot to considering genetic effects, were fit in K using analogous models to those with det-408 genotype interaction terms. Diet-genetic principal component interaction terms were excluded
- 409 from these models and individuals in cohort-reported race/ethnicity groups with less than five
- 409 momentee models and individuals in conort-reported face/enimetry groups with less than rive 410 members were excluded. Fixed effect meta-analysis of the CHO association (implicitly modeling
- 411 an exchange with FAT due to the additional dietary covariates) was conducted using the *meta*
- 412 package.

413 Variant follow-up

- 414 Sensitivity analysis was conducted to understand the impact of modeling choices on the
- 415 interaction effect estimates derived in the genome-wide analysis. These linear mixed models
- 416 were fit in R, with G×CHO interaction terms subject to fixed-effects meta-analysis using the
- 417 *meta* package as with the models without genotype effects. Some of these involved subsets of the
- 418 population: male and female subsets were tested separately, as well as subsets without obesity
- 419 (BMI < 30 kg/m²) and with and without prediabetes (defined as FG > 5.6 mmol/L or HbA1c >
- 420 5.7%). Additional models included adjustment for either smoking status (never/former/current,
- 421 coded as 0/1/2 and analyzed as a continuous variable), the Alternative Healthy Eating Index
- 422 2010(40) (a diet quality score), or a categorical coding of alcohol intake (none, modest [<1
- 423 drink/day for females or <2 drinks/day for males], or high), where available. These models with
- 424 additional covariate adjustments also included adjustment for their interactions with genotype.
- Finally, a model including genotype interaction terms for other main dietary components and
- 426 lifestyle confounders (total energy, protein, fiber, and alcohol) was included. This type of
- 427 residual confounding by genotype-covariate interaction terms has been previously
- 428 documented(41), but would have decreased statistical power if included in the genome-wide
- 429 analysis, especially for lower-frequency variants.
- 430 Variant rs79762542 was investigated in greater depth as the only variant reaching study-wide
- 431 significance. Based on its eQTL relationship impacting FRAS1 gene expression in thyroid from
- 432 the GTEx v8 dataset (<u>https://gtexportal.org/</u>), we tested for colocalization of this signal with the
- 433 carbohydrate interaction signal impacting HbA1c. Interaction summary statistics were retrieved
- in a window of 1Mb around the index variant rs79762542, and all thyroid-specific *cis*-eQTL
- 435 summary statistics related to *FRAS1* were retrieved from GTEx. Colocalization was tested using
- 436 the *coloc* package for R, assuming a single causal variant (*coloc.abf* function).

437 **Replication analysis in the UK Biobank**

- 438 UKB is a large prospective cohort with both deep phenotyping and molecular data, including
- 439 genome-wide genotyping, on over 500,000 individuals ages 40-69 living throughout the UK
- 440 between 2006-2010(42). Genotyping, imputation, and initial quality control on the genetic
- 441 dataset have been described previously(43). Analyses were conducted on genetic data release
- version 3, with imputation to a joint reference panel including the Haplotype Reference
- 443 Consortium and the 1000 Genomes Project (1KGP), under UK Biobank application 27892. This

work was conducted under a Not Human Subjects Research determination (NHSR-4298 at theBroad Institute of MIT and Harvard).

446

447 Ancestry group labels, genetic principal components, and labels defining an unrelated subset of

individuals were retrieved from the Pan-UKBB project (<u>https://pan.ukbb.broadinstitute.org/;</u> data

- retrieved from UKB return of results number 2442). Only unrelated individuals were used for
- analysis, with additional removal of individuals who were pregnant or had diabetes at the study
- 451 center visit. Two glycemic traits were available for testing in UKB: HbA1c and glucose
- 452 (collected as a random glucose measurement and later to remove non-fasting individuals).
- 453 Outliers for both traits (defined as more than 5 standard deviations from the mean) were 454 removed. Dietary data came from one or more Oxford WebO 24-hour dietary assessments(17
- removed. Dietary data came from one or more Oxford WebQ 24-hour dietary assessments(17)
 completed at the study center or during online follow-up over the course of approximately two
- 456 years. Daily nutrient intake estimates (calculated centrally by the UKB) were averaged across all
- 457 questionnaires for each individual and winsorized at three standard deviations from the mean.
- 458 After all exclusions, 178,352 individuals without diabetes had available genotype, biomarker,
- 459 and dietary data.
- 460

461 Regression analysis in the UKB mirrored that of the primary analysis, replacing cohort-reported

462 race/ethnicity with genetically-defined ancestry groups as defined by the Pan-UKBB project.

463 Given the larger sample size available, gene-covariate interactions were included for dietary

464 covariates (total energy, protein, fiber, and alcohol). When analyzing glucose, only the subset of

465 individuals with reported fasting times of at least eight hours were included, reducing the sample

466 size to 5,183. Due to the African ancestry-specificity of some of the top variants, a second

467 replication analysis was performed in the African-ancestry subset of UKB.

468 **Power Calculations**

469 Interaction test power calculations were performed using the *ESPRESSO.GxE* R package, which

- 470 uses a simulation-based approach to calculate empirical power estimates (given some sample
- 471 size) and sample size requirements (to achieve 80% power). The following parameters were
- 472 fixed for this analysis, chosen to mimic an analysis of HbA1c: random seed = 1, significance
- 473 threshold = 5×10^{-8} , phenotype mean = 5.5, phenotype standard deviation = 0.5, phenotype
- reliability = 1, genetic main effect = 0.1, exposure mean = 0, exposure standard deviation = 1,
- 475 exposure main effect = 0.2. The following parameters were varied: interaction effect $\{0.025, 0.0275, 0.0275, 0.0275, 0.01, 0.05, 0.05, 0.05, 0$
- 476 0.0375, 0.05, 0.0625, 0.075, 0.0875, 0.1}, MAF {0.01, 0.05, 0.1, 0.5}, and exposure reliability
- 477 {0.25, 0.5, 0.75, 1}. Here, reliability is used to quantify the simulated measurement error of the
 478 phenotype and exposure and is equivalent to an intraclass correlation coefficient (ratio of
- 478 phenotype and exposure and is equivalent to an intractass correlation coefficient (ratio of 479 between-subject variance to total [between-subject plus measurement error] variance).
- 480 To enable simulation-based power calculations for aggregate tests of rare variants while
- 481 accounting for exposure measurement error, we developed an extension of the *ESPRESSO.GxE*
- 482 package, called *ESPRESSO.GxE.RV*. In this extension, the basic structure of the simulations
- 483 remains the same, but an additional parameter allows the user to specify a number of variants
- 484 (M) to test in aggregate. Within each simulation run, M variants are simulated, with some portion
- 485 having equal interaction and main effects on the outcome (according to a user-specified causal
- 486 variant fraction) and the rest generated randomly. The final p-value from that simulation is

- 487 calculated using Fisher's method on the full set of M p-values. The following parameters were
- 488 given different values for this set of simulations: interaction effect {0.025, 0.05, 0.075, 0.1,
- 489 0.125, 0.15, 0.175, 0.2}, MAF {0.0025, 0.005, 0.0075, 0.01}. Other parameters were specific to
- 490 rare variant tests: number of variants per aggregate test $\{1, 5, 10, 20\}$ and causal fraction $\{0.1, 0.25, 0.5, 1\}$
- 491 0.25, 0.5, 1}. Code for this extension of the package can be found on GitHub:
- 492 <u>https://github.com/kwesterman/ESPRESSO.GxE.RV</u>.

493 To provide context for realistic gene-diet interaction effect sizes despite few well-replicated

- 494 examples of such interactions for glycemic traits in the literature, we retrieved results from
- variants reaching significance in a recent trans-ancestry GWAS for HbA1c(21) and an estimated
- 496 effect for the carbohydrate-HbA1c relationship from a recent nutritional epidemiological
- 497 analysis(27).
- 498

499 AUTHOR CONTRIBUTIONS

500

501 KEW, MEW, JM, and AKM designed the research. KEW, SMG, JW, DKT, and AKM

502 contributed to the harmonization of glycemic trait variables across studies; KEW conducted the

503 research and performed the primary data analysis; JCF, JBM, DKT, HC, and AKM supervised

the research; KEW and MEW wrote the manuscript; all additional authors contributed to the
collection and curation of the study-specific or TOPMed-wide datasets; KEW and AKM had
primary responsibility for the final content. All authors read and approved the final manuscript:
KEW, MEW, SMG, JW, DD, JM, AA, SA, ASB, AGB, MLB, JAB, YIC, JD, MOG, XG, NRH,
AH, BH, MRI, WCJ, RRK, LL, RNL, CL, SL, JM, RN, JSP, MP, LR, LJR, ES, MKS, AHS,
AVS, NLS, LS, ST, KDT, PSD, JGW, ACW, LRY, JY, YZ, EB, ACM, MF, TPR, BMP, DL,

- 510 NLH, VSR, RAM, DKA, RK, KEN, AC, AC, JR, SSR, JEM, APR, CK, JCF, JBM, JM, DKT, 511 HC, AKM.
- 512

513 ACKNOWLEDGMENTS

514

515 The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the

516 Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA,

517 NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained

- 518 from the GTEx Portal on 03/28/2022.
- 519

520 Support for this work was provided by the National Institutes of Health, National Heart, Lung,

and Blood Institute, through the BioData Catalyst program (award 10T3HL142479-01,

- 522 10T3HL142478-01, 10T3HL142481-01, 10T3HL142480-01, 10T3HL147154-01). Any
- 523 opinions expressed in this document are those of the author(s) and do not necessarily reflect the
- views of NHLBI, individual BioData Catalyst team members, or affiliated organizations and
- 525 institutions. Further, the authors wish to acknowledge the contributions of the consortium
- 526 working on the development of the NHLBI BioData Catalyst ecosystem.
- 527
- 528 The authors would also like to acknowledge the contributions of L. Adrienne Cupples to the
- 529 Framingham Heart Study and the TOPMed program.
- 530

531 **TOPMed Acknowledgments**

532 Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program was supported by

the National Heart, Lung and Blood Institute (NHLBI). See the TOPMed Omics Support Table

- below for study specific omics support information. Core support including centralized genomic
- read mapping and genotype calling, along with variant quality metrics and filtering were
- 536 provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract
- 537 HHSN268201800002I). Core support including phenotype harmonization, data management,
- sample-identity QC, and general program coordination were provided by the TOPMed Data
- 539 Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). We
- 540 gratefully acknowledge the studies and participants who provided biological samples and data
- 541 for TOPMed.

Study	Acknowledgements					
	ARIC: The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (75N92022D00001, 75N92022D00002, 75N92022D00003, 75N92022D00004, 75N92022D00005). The authors thank the staff and participants of the ARIC study for their important contributions.					
Atherosclerosis Risk in Communities study	WGS for "NHLBI TOPMed: Atherosclerosis Risk in Communities (ARIC)" (phs001211) was performed at the Baylor College of Medicine Human Genome Sequencing Center (HHSN268201500015C and 3U54HG003273-12S2) and the Broad Institute for MIT and Harvard (3R01HL092577-06S1).					
	The Genome Sequencing Program (GSP) was funded by the National Human Genome Research Institute (NHGRI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Eye Institute (NEI). The GSP Coordinating Center (U24 HG008956) contributed to cross program scientific initiatives and provided logistical and general study coordination. The Centers for Common Disease Genomics (CCDG) program was supported by NHGRI and NHLBI, and whole genome sequencing was performed at the Baylor College of Medicine Human Genome Sequencing Center (UM1 HG008898).					
CARDIA	The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (HHSN268201800005I & HHSN268201800007I), Northwestern University (HHSN268201800003I), University of Minnesota (HHSN268201800006I), and Kaiser Foundation Research Institute (HHSN268201800004I). CARDIA was also partially supported by the Intramural Research Program of the National Institute on Aging (NIA) and an intra agency agreement between NIA and NHLBI (AG0005).					

CHS	This research was supported by contracts 75N92021D00006, HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grants R01HL120393, U01HL080295 and U01HL130114 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Framingham Heart Study	WGS for "NHLBI TOPMed: Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study (phs000974.v1.p1) was performed at the Broad Institute of MIT and Harvard (3R01HL092577-06S1 (AFGen)). This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine. The Framingham Heart Study (FHS) acknowledges the support of contracts NO1-HC-25195, HHSN268201500001I and 75N92019D00031 from the National Heart, Lung and Blood Institute and grant supplement R01 HL092577-06S1 for this research. We also acknowledge the dedication of the FHS study participants without whom this research would not be possible.
GeneSTAR	GeneSTAR was supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute (U01 HL72518, HL087698, HL49762, HL59684, HL58625, HL071025, HL092165, HL099747, K23HL105897, HL112064), by grants from the National Institutes of Health/National Institute of Nursing Research (NR0224103, NR008153), by a grant from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NS062059), by a grant from the National Institutes of Health/National Center for Research Resources (M01-RR000052) to the Johns Hopkins General Clinical Research Center, and by a grant from the National Center for Advancing Translational Sciences, National Institutes of Health (UL1TR001079) to the Johns Hopkins Institute for Clinical & Translational Research.
GOLDN	GOLDN biospecimens, baseline phenotype data, and intervention phenotype data were collected with funding from National Heart, Lung and Blood Institute (NHLBI) grant U01 HL072524. Whole-genome sequencing in GOLDN was funded by NHLBI grant R01 HL104135-04S1. We thank GOLDN participants and investigators for their significant contributions.
HCHS/SOL	The Hispanic Community Health Study/Study of Latinos is a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (HHSN268201300001I / N01-HC-65233), University of Miami (HHSN268201300004I / N01-HC- 65234), Albert Einstein College of Medicine (HHSN268201300002I / N01- HC-65235), University of Illinois at Chicago – HHSN268201300003I / N01- HC-65236 Northwestern Univ), and San Diego State University

	(HHSN2682013000051 / N01-HC-65237). The following Institutes/Centers/Offices have contributed to the HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, NIH Institution-Office of Dietary Supplements.
JHS	The Jackson Heart Study is supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN268201800015I) and the University of Mississippi Medical Center (HHSN268201800010I, HHSN268201800011I and HHSN268201800012I) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Minority Health and Health Disparities (NIMHD). The authors thank the participants and data collection staff of the Jackson Heart Study. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.
MESA	Whole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). WGS for "NHLBI TOPMed: Multi-Ethnic Study of Atherosclerosis (MESA)" (phs001416.v1.p1) was performed at the Broad Institute of MIT and Harvard (3U54HG003067-13S1). Centralized read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL- 117626-02S1). Phenotype harmonization, data management, sample-identity QC, and general study coordination, were provided by the TOPMed Data Coordinating Center (3R01HL-120393-02S1), and TOPMed MESA Multi- Omics (HHSN2682015000031/HSN26800004). The MESA projects are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for the Multi- Ethnic Study of Atherosclerosis (MESA) projects are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for the Multi- Ethnic Study of Atherosclerosis (MESA) projects are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95161, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR- 000040, UL1-TR-001079, UL1-TR-001420, UL1TR001881, DK063491, and R01HL105756. The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A fill list of participating MESA investigators and institutes can be found

	at <u>http://www.mesa-nhlbi.org</u> . Also supported in part by the NHLBI contracts
	R01HL151855 and R01HL146860.
	The WHI program is funded by the National Heart, Lung, and Blood Institute,
WHI	National Institutes of Health, U.S. Department of Health and Human Services
****	through contracts 75N92021D00001, 75N92021D00002, 75N92021D00003,
	75N92021D00004, 75N92021D00005.

542

543 Data described in the manuscript will be made available upon request pending application and

544 approval from NHLBI Trans-Omics for Precision Medicine (TOPMed) program.

REFERENCES

- 1. Ajala O, English P, Pinkney J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr 2013;97:505–16.
- Salas-Salvadó J, Bulló M, Babio N, Martínez-González MÁ, Ibarrola-Jurado N, Basora J, Estruch R, Covas MI, Corella D, Arós F, et al. Reduction in the Incidence of Type 2 Diabetes With the Mediterranean Diet. Diabetes Care 2011;34:14–9.
- 3. The Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP). Diabetes Care 2002;25:2165–71.
- 4. Davis NJ, Tomuta N, Schechter C, Isasi CR, Segal-Isaacson CJ, Stein D, Zonszein J, Wylie-Rosett J. Comparative Study of the Effects of a 1-Year Dietary Intervention of a Low-Carbohydrate Diet Versus a Low-Fat Diet on Weight and Glycemic Control in Type 2 Diabetes. Diabetes Care 2009;32:1147–52.
- 5. Korem T, Zeevi D, Zmora N, Weissbrod O, Bar N, Lotan-Pompan M, Avnit-Sagi T, Kosower N, Malka G, Rein M, et al. Bread Affects Clinical Parameters and Induces Gut Microbiome-Associated Personal Glycemic Responses. Cell Metab 2017;
- 6. Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, Capdevila J, Hadjigeorgiou G, Davies R, Al Khatib H, et al. Human postprandial responses to food and potential for precision nutrition. Nat Med 2020;26:964–73.
- 7. Bachmann AM, Morel J-D, El Alam G, Rodríguez-López S, Imamura de lima T, Goeminne LJE, Benegiamo G, Loric S, Conti M, Sleiman MB, et al. Genetic background and sex control the outcome of high-fat diet feeding in mice. iScience 2022;25:104468.
- 8. Barrington WT, Wulfridge P, Wells AE, Rojas CM, Howe SYF, Perry A, Hua K, Pellizzon MA, Hansen KD, Voy BH, et al. Improving Metabolic Health Through Precision Dietetics in Mice. Genetics 2018;208:399–417.
- 9. Qi B, Bray GA, Hu FB, Sacks FM, Qi L. Weight-loss diets modify glucose-dependent insulinotropic polypeptide receptor rs2287019 genotype effects on changes in body weight, fasting glucose, and insulin resistance: The preventing overweight using novel dietary strategies trial. Am J Clin Nutr 2012;95.
- Corella D, Carrasco P, Sorli J V., Estruch R, Rico-Sanz J, Martinez-Gonzalez MA, Salas-Salvado J, Covas MI, Coltell O, Aros F, et al. Mediterranean Diet Reduces the Adverse Effect of the TCF7L2-rs7903146 Polymorphism on Cardiovascular Risk Factors and Stroke Incidence: A randomized controlled trial in a high-cardiovascular-risk population. Diabetes Care 2013;36:3803–11.
- 11. Westerman KE, Miao J, Chasman DI, Florez JC, Chen H, Manning AK, Cole JB. Genome-wide gene-diet interaction analysis in the UK Biobank identifies novel effects on hemoglobin A1c. Hum Mol Genet 2021;
- 12. Francis M, Li C, Sun Y, Zhou J, Li X, Brenna JT, Ye K. Genome-wide association study of fish oil supplementation on lipid traits in 81,246 individuals reveals new gene-diet interaction loci. Cordell HJ, editor. PLOS Genet 2021;17:e1009431.
- 13. Franks PW, Merino J. Gene-lifestyle interplay in type 2 diabetes. Curr Opin Genet Dev 2018;50:35–40.
- Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, Payne AJ, Steinthorsdottir V, Scott RA, Grarup N, et al. Fine-mapping type 2 diabetes loci to singlevariant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 2018;50:1505–13.

- 15. Fadista J, Manning AK, Florez JC, Groop L. The (in)famous GWAS P-value threshold revisited and updated for low-frequency variants. Eur J Hum Genet 2016;24:1202–5.
- Zou Y, Gong N, Cui Y, Wang X, Cui A, Chen Q, Jiao T, Dong X, Yang H, Zhang S, et al. Forkhead Box P1 (FOXP1) Transcription Factor Regulates Hepatic Glucose Homeostasis. J Biol Chem 2015;290:30607–15.
- Liu B, Young H, Crowe FL, Benson VS, Spencer EA, Key TJ, Appleby PN, Beral V. Development and evaluation of the Oxford WebQ, a low-cost, web-based method for assessment of previous 24 h dietary intakes in large-scale prospective studies. Public Health Nutr 2011;14:1998–2005.
- 18. Wong M, Day N, Luan J, Chan K, Wareham N. The detection of gene–environment interaction for continuous traits: should we deal with measurement error by bigger studies or better measurement? Int J Epidemiol 2003;32:51–7.
- 19. Osazuwa-Peters OL, Schwander K, Waken RJ, de las Fuentes L, Kilpeläinen TO, Loos RJF, Racette SB, Sung YJ, Rao DC. The Promise of Selecting Individuals from the Extremes of Exposure in the Analysis of Gene-Physical Activity Interactions. Hum Hered 2018;83:315–32.
- 20. Jurgens SJ, Choi SH, Morrill VN, Chaffin M, Pirruccello JP, Halford JL, Weng L-C, Nauffal V, Roselli C, Hall AW, et al. Analysis of rare genetic variation underlying cardiometabolic diseases and traits among 200,000 individuals in the UK Biobank. Nat Genet 2022;
- 21. Wheeler E, Leong A, Liu C-T, Hivert M-F, Strawbridge RJ, Podmore C, Li M, Yao J, Sim X, Hong J, et al. Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. Gregg E, editor. PLOS Med 2017;14:e1002383.
- 22. Arnold KF, Berrie L, Tennant PWG, Gilthorpe MS. A causal inference perspective on the analysis of compositional data. Int J Epidemiol 2020;49:1307–13.
- 23. Salmerón J, Hu FB, Manson JE, Stampfer MJ, Colditz GA, Rimm EB, Willett WC. Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr 2001;73:1019–26.
- 24. Merino J, Guasch-Ferré M, Ellervik C, Dashti HS, Sharp SJ, Wu P, Overvad K, Sarnowski C, Kuokkanen M, Lemaitre RN, et al. Quality of dietary fat and genetic risk of type 2 diabetes: individual participant data meta-analysis. BMJ 2019;14292.
- 25. Harding A-H, Sargeant LA, Welch A, Oakes S, Luben RN, Bingham S, Day NE, Khaw K-T, Wareham NJ. Fat Consumption and HbA1c Levels. Diabetes Care 2001;24:1911–6.
- 26. Imamura F, Micha R, Wu JHY, de Oliveira Otto MC, Otite FO, Abioye AI, Mozaffarian D. Effects of Saturated Fat, Polyunsaturated Fat, Monounsaturated Fat, and Carbohydrate on Glucose-Insulin Homeostasis: A Systematic Review and Meta-analysis of Randomised Controlled Feeding Trials. Ma RCW, editor. PLOS Med 2016;13:e1002087.
- 27. Churuangsuk C, Lean MEJ, Combet E. Lower carbohydrate and higher fat intakes are associated with higher hemoglobin A1c: findings from the UK National Diet and Nutrition Survey 2008–2016. Eur J Nutr 2020;59:2771–82.
- 28. Pérusse L, Bouchard C. Gene-diet interactions in obesity. Am J Clin Nutr 2000;72:1285s-1290s.
- 29. Gaye A, Burton TWY, Burton PR. ESPRESSO: Taking into account assessment errors on outcome and exposures in power analysis for association studies. Bioinformatics 2015;31.
- 30. Dahl A, Nguyen K, Cai N, Gandal MJ, Flint J, Zaitlen N. A Robust Method Uncovers Significant Context-Specific Heritability in Diverse Complex Traits. Am J Hum Genet

2020;106:71-91.

- Zheng J-S, Arnett DK, Lee Y-C, Shen J, Parnell LD, Smith CE, Richardson K, Li D, Borecki IB, Ordovás JM, et al. Genome-Wide Contribution of Genotype by Environment Interaction to Variation of Diabetes-Related Traits. PLoS One 2013;8:e77442.
- 32. Oster E. Health Recommendations and Selection in Health Behaviors. Am Econ Rev Insights 2020;2:143–60.
- 33. Conomos MP, Miller MB, Thornton TA. Robust Inference of Population Structure for Ancestry Prediction and Correction of Stratification in the Presence of Relatedness. Genet Epidemiol 2015;39:276–93.
- 34. Conomos MP, Reiner AP, Weir BS, Thornton TA. Model-free Estimation of Recent Genetic Relatedness. Am J Hum Genet 2016;98:127–48.
- 35. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2021.
- 36. The NHLBI BioData Catalyst. National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services; 2020.
- 37. Wang X, Lim E, Liu CT, Sung YJ, Rao DC, Morrison AC, Boerwinkle E, Manning AK, Chen H. Efficient gene–environment interaction tests for large biobank-scale sequencing studies. Genet Epidemiol 2020;44.
- 38. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010;26:2190–1.
- 39. Manning AK, LaValley M, Liu C-T, Rice K, An P, Liu Y, Miljkovic I, Rasmussen-Torvik L, Harris TB, Province MA, et al. Meta-analysis of gene-environment interaction: joint estimation of SNP and SNP × environment regression coefficients. Genet Epidemiol 2011;35:11–8.
- Chiuve SE, Fung TT, Rimm EB, Hu FB, McCullough ML, Wang M, Stampfer MJ, Willett WC. Alternative Dietary Indices Both Strongly Predict Risk of Chronic Disease. J Nutr 2012;142:1009–18.
- Keller MC. Gene × Environment Interaction Studies Have Not Properly Controlled for Potential Confounders: The Problem and the (Simple) Solution. Biol Psychiatry 2014;75:18–24.
- 42. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Med 2015;12:e1001779.
- 43. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018;562:203–9.

TABLES

Trait	rsID	Chromosome	Effect	Avg.	Main effect	Interaction	P _{interaction}
			Allele	EAF	estimate	estimate	
HbA1c	ma70762542		G	G 0.03	-0.013 [-0.038-	0.048 [0.031-	1.1×10 ⁻⁸
HUAIC	rs79762542	4	U	0.05	0.012]	0.064]	1.1×10
FG	ma1200604	2	C	0.61	-0.003 [-0.011-	0.016 [0.01-	1.9×10 ⁻⁸
гu	rs1288694	5	C	0.01	0.004]	0.022]	1.9×10
lnFI	rs782681704	Х	G	0.01	-0.049 [-0.209-	0.284 [0.182-	4.6×10 ⁻⁸
шгі	18/02001/04	А	G	0.01	0.11]	0.385]	4.0×10

Table 1: Top variants interacting with carbohydrate intake from the common-variant GWIS.

Interaction estimates with 95% CIs are given in units of [trait units / allele / 250 kcal carbohydrate]. All variants passed a significance threshold of $P_{interaction} < 5 \times 10^{-8}$.